Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jan;73(1):31-38.
doi: 10.1053/j.ajkd.2018.07.016. Epub 2018 Oct 2.

Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants

Affiliations
Free PMC article
Randomized Controlled Trial

Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants

Girish N Nadkarni et al. Am J Kidney Dis. 2019 Jan.
Free PMC article

Abstract

Rationale & objective: Random assignment to intensive blood pressure (BP) lowering (systolic BP<120mmHg) compared to a less intensive BP target (systolic BP<140mmHg) in the Action to Control Cardiovascular Risk in Diabetes BP (ACCORD-BP) trial resulted in a more rapid decline in estimated glomerular filtration rate (eGFR). Whether this reflects hemodynamic effects or intrinsic kidney damage is unknown.

Study design: Longitudinal analysis of a subgroup of clinical trial participants.

Settings & participants: A subgroup of 529 participants in ACCORD-BP.

Exposures: Urine biomarkers of tubular injury (kidney injury molecule 1, interleukin 18 [IL-18]), repair (human cartilage glycoprotein 39 [YKL-40]), and inflammation (monocyte chemoattractant protein 1) at baseline and year 2.

Outcomes: Changes in eGFR from baseline to 2 years.

Analytical approach: We compared changes in biomarker levels and eGFRs across participants treated to an intensive versus less intensive BP goal using analysis of covariance.

Results: Of 529 participants, 260 had been randomly assigned to the intensive and 269 to the standard BP arm. Mean age was 62±6.5 years and eGFR was 90mL/min/1.73m2. Baseline clinical characteristics, eGFRs, urinary albumin-creatinine ratios (ACRs), and urinary biomarker levels were similar across BP treatment groups. Compared to less intensive BP treatment, eGFR was 9.2mL/min/1.73m2 lower in the intensive BP treatment group at year 2. Despite the eGFR reduction, within this treatment group, ACR was 30% lower and 4 urinary biomarker levels were unchanged or lower at year 2. Also within this group, participants with the largest declines in eGFRs had greater reductions in urinary IL-18 and YKL-40 levels. In a subgroup analysis of participants developing incident chronic kidney disease (sustained 30% decline and eGFR<60mL/min/1.73m2; n=77), neither ACR nor 4 biomarker levels increased in the intensive treatment group, whereas the level of 1 biomarker, IL-18, increased in the less intensive treatment group.

Limitations: Few participants with advanced baseline chronic kidney disease. Comparisons across treatment groups do not represent comparisons of treatment arms created solely through randomization.

Conclusions: Among a subset of ACCORD-BP trial participants, intensive BP control was associated with reductions in eGFRs, but not with an increase in injury marker levels. These findings support that eGFR decline observed with intensive BP goals in ACCORD participants may predominantly reflect hemodynamic alterations.

Keywords: CKD progression; Chronic kidney disease (CKD); blood pressure (BP); eGFR decline; estimated glomerular filtration rate (eGFR); hemodynamics; hypertension; intensive BP control; kidney tubule; renal perfusion; tubular injury; urinary biomarkers; urine.

Figures

Figure 1.
Figure 1.. Effects of Intensive Blood Pressure Control vs. Standard Control on Estimated GFR, Albuminuria and Urine Tubular Damage Markers in Participants in ACCORD.
Geometric least squares mean ratios (GLSMRs) were calculated by dividing the antilog of the the predicted population means (LSMs) of intensive and standard BP.
Figure 2a.
Figure 2a.. Changes in estimated GFR and Tubule Damage Biomarkers observed Among Participants who were treated to an intensive BP goal and Developed CKD
This figure shows the percentage change from baseline to 24 months for eGFR, albuminuria and kidney tubule injury biomarkers (KIM-1; IL-18; MCP-1 and YKL-40) in those participants who developed CKD. CKD was defined as a ≥ 30% decline from baseline on two or more values and eGFR <60 ml/min/1.73m2 during the 5-year follow-up. ANCOVA was also used to evaluate change in urinary biomarkers (baseline to 2 year) and their association with CKD, by treatment arms. The model was adjusted for covariates including age, gender, race, baseline eGFR, ACEi/ARB, linear and quadratic urine creatinine (log2 transformed) values for each visit.
Figure 2b.
Figure 2b.. Changes in estimated GFR and Tubule Damage Biomarkers observed Among Participants who were treated to a less intensive BP goal and Developed CKD
This figure shows the percentage change from baseline to 24 months for eGFR, albuminuria and kidney tubule injury biomarkers (KIM-1; IL-18; MCP-1 and YKL-40) in those participants who developed CKD. CKD was defined as a ≥ 30% decline from baseline on two or more values and eGFR <60 ml/min/1.73m2 during the 5-year follow-up. ANCOVA was also used to evaluate change in urinary biomarkers (baseline to 2 year) and their association with CKD, by treatment arms. The model was adjusted for covariates including age, gender, race, baseline eGFR, ACEi/ARB, linear and quadratic urine creatinine (log2 transformed) values for each visit.

Comment in

Similar articles

Cited by 14 articles

Publication types